Hibercell
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
619 W 54th St Fl 8, New York, New York, ...Phone Number
(651) 675-0300Website
www.hibercell.comRevenue
$11.6 MillionIndustry
About Hibercell
HiberCell is focused on developing innovative therapies that target adaptive-stress driven vulnerabilities in cancer cells to combat treatment resistance, cancer relapse, and metastasis. Their clinical-stage therapeutic candidates, including HC-7366, HC-5404, and Odetiglucan, aim to exploit stress-induced vulnerabilities to enhance patient outcomes. The company is led by a team of experienced biotech executives committed to combining traditional drug development with computational expertise. HiberCell's mission is to improve the lives of cancer patients by pioneering new treatment paradigms.Explore more
Hibercell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Hibercell
Compare insights from companies similar to Hibercell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
1997
JA
Joseph AttawayChief Financial Officer & Shareholder & Partner & Co-Founder
Hibercell Tech Stack
A closer look at the technologies used by Hibercell
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hibercell
Sign Up For FreeTo access detailed company insights
HiberCell is focused on developing innovative therapies that target adaptive-stress driven vulnerabilities in cancer cells to combat treatment resistance, cancer relapse, and metastasis. Their clinical-stage therapeutic candidates, including HC-7366, HC-5404, and Odetiglucan, aim to exploit stress-induced vulnerabilities to enhance patient outcomes... Read More
